The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting.

Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study / Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Rimassa, Lorenza; Presa, José; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamoto, Hideki; Aoki, Tomoko; Chon, Hong Jae; Himmelsbach, Vera; Pressiani, Tiziana; Kawaguchi, Takumi; Montes, Margarida; Vivaldi, Caterina; Soldà, Caterina; Piscaglia, Fabio; Hiraoka, Atsushi; Sho, Takuya; Niizeki, Takashi; Nishida, Naoshi; Steup, Christoph; Iavarone, Massimo; Di Costanzo, Giovanni; Marra, Fabio; Scartozzi, Mario; Tamburini, Emiliano; Cabibbo, Giuseppe; Foschi, Francesco Giuseppe; Silletta, Marianna; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Fukunishi, Shinya; Tsuji, Kunihiko; Ishikawa, Toru; Tajiri, Kazuto; Ochi, Hironori; Yasuda, Satoshi; Toyoda, Hidenori; Ogawa, Chikara; Nishimura, Takashi; Hatanaka, Takeshi; Kakizaki, Satoru; Shimada, Noritomo; Kawata, Kazuhito; Tada, Fujimasa; Ohama, Hideko; Nouso, Kazuhiro; Morishita, Asahiro; Tsutsui, Akemi; Nagano, Takuya; Itokawa, Norio; Okubo, Tomomi; Arai, Taeang; Imai, Michitaka; Kosaka, Hisashi; Naganuma, Atsushi; Koizumi, Yohei; Nakamura, Shinichiro; Kaibori, Masaki; Iijima, Hiroko; Hiasa, Yoichi; Cammarota, Antonella; Burgio, Valentina; Cascinu, Stefano; Casadei-Gardini, Andrea. - In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. - ISSN 0171-5216. - 149:9(2023), pp. 5591-5602. [Epub ahead of print] [10.1007/s00432-022-04512-1]

Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Rimini, Margherita;Cascinu, Stefano;Casadei-Gardini, Andrea
2023-01-01

Abstract

The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting.
2023
Advanced HCC
Atezolizumab plus bevacizumab
First-line therapy
Lenvatinib
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/134753
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 22
social impact